

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	491	544/144.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:29
L2	1102	548/465.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:29
L3	1464	I1 or I2	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:29
L4	597	544/137.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:31
L5	2033	I3 or I4	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:31
L6	148	I5 and thrombosis	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:32
L7	0	I5 and antibacteria	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:32

EAST Search History

L8	210	I5 and antibacteria\$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:33
L9	337	I6 or I8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/18 11:32

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPlus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPlus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPlus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPlus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEMLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPlus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:17:22 ON 18 JAN 2008

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:17:31 ON 18 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9

DICTIONARY FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524623\1.str



```

chain nodes :
14 15 16 17 18 19 20 21 22 30 32 33 35 36 37 47 48 49 50
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 38 39 40 41 42 43 44 45 46
chain bonds :
2-33 3-7 4-32 6-30 14-17 14-18 15-19 15-20 16-21 16-22 30-35 30-50
35-36 36-37 36-49 37-38 39-47 42-48
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 38-39 38-42
39-40 40-41 40-43 41-42 41-46 43-44 44-45 45-46
exact/norm bonds :
2-33 3-7 4-32 6-30 7-8 7-12 8-9 9-10 10-11 11-12 14-17 14-18 15-19
15-20 16-21 16-22 30-35 30-50 35-36 36-37 36-49 37-38 38-39 38-42 39-40
39-47 41-42 42-48
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 40-41 40-43 41-46 43-44 44-45 45-46

```

G1:O,S

G2:[*1],[*2],[*3]

G3:[*1],[*2]

G4:H,X

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 30:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS
37:CLASS 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 47:CLASS 48:CL Searched by Jason M. Nolan, Ph.D.

```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:17:52 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 2 TO 124

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full ✓

FULL SEARCH INITIATED 10:17:58 FILE 'REGISTRY' ✓

FULL SCREEN SEARCH COMPLETED 18 TO ITERATE

100.0% PROCESSED ✓ 18 ITERATIONS

SEARCH TIME: 00.00.01

2 ANSWERS

L3 2 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 10:18:07 ON 18 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jan 2008 VOL 148 ISS 4

FILE LAST UPDATED: 17 Jan 2008 (20080117/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 7 L3

=> d ibib abs hitstr 1-7




L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:410196 CAPLUS
 DOCUMENT NUMBER: 146:421970
 TITLE: Preparation of oxazolidinones for the treatment of cerebral circulatory disorders
 INVENTOR(S): Perzborn, Elisabeth; Krahn, Thomas
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: PCT Int. Appl., 132pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007039134	A1	20070412	WO 2006-EP9204	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, ML, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: DE 2005-102005047558A 20051004

OTHER SOURCE(S): MARPAT 146:421970
 GI




AB Title compds. I [R1 = substituted 2-thiophene with provisos; R2 = D-A-; A

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:409419 CAPLUS
 DOCUMENT NUMBER: 146:421968
 TITLE: Preparation of oxazolidinones for the treatment of microangiopathy
 INVENTOR(S): Perzborn, Elisabeth; Misselwitz, Frank
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
 SOURCE: Ger. Offen., 84pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102005048824	A1	20070412	DE 2005-102005048824	20051010
WO 2007042146	A1	20070419	WO 2006-EP9373	20060927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, ML, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: DE 2005-102005048824A 20051010


OTHER SOURCE(S): MARPAT 146:421968
 GI



AB Title compds. I [R1 = substituted 2-thiophene with provisos; R2 = D-A-; A = phenylene; D = 5- or 6-membered heterocycle; R3, R4, R5, R6, R7, R8 = H]

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 = phenylene; D = 5- or 6-membered heterocycle; R3, R4, R5, R6, R7, R8 = H]
 and their pharmaceutically acceptable salts and formulations were prep. For example, coupling of amine II and 5-chlorothiophene-2-carboxylic acid afforded oxazolidinone III. In a blood-coagulation factor Xa inhibition assay, compd. III exhibited an IC50 value of 43 nM.
 IT 446292-07-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones for treatment of cerebral circulatory disorders)
 RN 446292-07-5 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 and their pharmaceutically acceptable salts and formulations were prep. For example, coupling of amine II and 5-chlorothiophene-2-carboxylic acid afforded oxazolidinone III. In a blood-coagulation factor Xa inhibition assay, oxazolidinone III exhibited an IC50 value of 43 nM.
 IT 446292-07-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones for treatment of microangiopathy)
 RN 446292-07-5 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:77302 CAPLUS
 DOCUMENT NUMBER: 144:170978
 TITLE: A process for the preparation of novel intermediates for linezolid and related compounds
 INVENTOR(S): Mohan Rao, Dodda; Krishna Reddy, Pingili
 PATENT ASSIGNEE(S): Symed Labs Limited, India
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2006008754 A1 20060126 WO 2004-IN218 20040720
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 EP 1768967 A1 20070404 EP 2004-770673 20040720
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 US 2006247435 A1 20061102 US 2005-524623 20050216
 PRIORITY APPLN. INFO.: WO 2004-IN218 W 20040720

OTHER SOURCE(S): CASREACT 144:170978; MARPAT 144:170978
 GI

Instant App.


7/20/04

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The invention provides a process for preparation of 5-aminomethyl-substituted oxazolidinones of formula I, key intermediates for oxazolidinone antibacterials including linezolid. Comps. of formula I wherein X is O, S, SO, or SO₂; R₁ is H, Me, or CN; R₂ is independently H, F, or Cl; R₃ is H or Me; n is 0, 1, or 2; and their derivs. are claimed in this invention. Thus, the key intermediate II of linezolid was prepared by reacting N-[3-chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinylaniline with potassium phthalimide then subjecting the resulting N-[3-phthalimido-2-(R)-hydroxypropyl]-3-fluoro-4-(morpholinyl)aniline to carbonylation to give
 (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide, which reacted with hydrazine hydrate to produce (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]amine (II).
 IT 874340-08-6P, N-(3-Phthalimido-2-(R)-hydroxypropyl)-3-fluoro-4-(morpholinyl)aniline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (a process for the preparation of novel intermediates for linezolid and related compds.)
 RN 874340-08-6 CAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-[(2R)-3-[[3-fluoro-4-(4-morpholinyl)phenyl]amino]-2-hydroxypropyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:810223 CAPLUS
 DOCUMENT NUMBER: 143:318362
 TITLE: Discovery of the Novel Antithrombotic Agent
 5-Chloro-N-((5S)-2-oxo-3-[[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor
 AUTHOR(S): Roehrig, Susanne; Straub, Alexander; Pohlmann, Jens; Lampe, Thomas; Pernstorfer, Josef; Schlemmer, Karl-Heinz; Reinemer, Peter; Perzborn, Elisabeth
 CORPORATE SOURCE: Bayer HealthCare AG, Wuppertal, D-42096, Germany
 SOURCE: Journal of Medicinal Chemistry (2005), 48(19), 5900-5908
 CODEN: JMCMAH; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:318362
 AB Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising target, and recent efforts in this field have focused on the identification of small-mol. inhibitors with good oral bioavailability. We identified oxazolidinone derivs. as a new class of potent FXa inhibitors. Lead optimization led to the discovery of BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity. The X-ray crystal structure of 5 in complex with human FXa clarified the binding mode and the stringent requirements for high affinity. The interaction of the neutral ligand chlorothiophene in the S1 subsite allows for the combination of good oral bioavailability and high potency for nonbasic 5. Compound 5 is currently under clin. development for the prevention and treatment of thromboembolic diseases.
 IT 446292-07-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (oxazolidinones preparation, factor Xa inhibition and structure-related oral antithrombotic action)
 RN 446292-07-5 CAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2005:673289 CAPLUS
DOCUMENT NUMBER: 143:172902
TITLE: Preparation of rivaroxaban
INVENTOR(S): Berwe, Mathias; Thomas, Christian; Rehse, Joachim; Grotjohann, Dirk
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Rivaroxaban

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068456	A1	20050728	WO 2004-EP14870	20041231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004002044	A1	20050804	DE 2004-102004002044	20040115
AU 2004313694	A1	20050728	AU 2004-313694	20041231
CA 2553237	A1	20050728	CA 2004-2553237	20041231
EP 1720866	A1	20061115	EP 2004-804455	20041231
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1906191	A	20070131	CN 2004-80040552	20041231
BR 2004018405	A	20070515	BR 2004-18405	20041231
JP 2007517816	T	20070705	JP 2006-548182	20041231
US 2005182055	A1	20050818	US 2005-32815	20050110
IN 2006DN03734	A	20070420	IN 2006-DN3734	20060629
MX 2006PA07902	A	20060926	MX 2006-PA7902	20060710
NO 2006003677	A	20061011	NO 2006-3677	20060815
PRIORITY APPLN. INFO.:				DE 2004-102004002044A 20040115
				WO 2004-EP14870 W 20041231

OTHER SOURCE(S): CASREACT 143:172902
GI


L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compound I [Rivaroxaban] was prepared For example, N-acylation of amine
II with 2-chloro-5-carboxythiophene afforded title compound I in 98.7% yield.

IT 446292-07-5p
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of rivaroxaban)
RN 446292-07-5 CAPLUS
CN 1H-Indole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:5775 CAPLUS
DOCUMENT NUMBER: 138:89797
TITLE: Preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases
INVENTOR(S): Straub, Alexander; Lampe, Thomas; Farneser, Josef; Perle, Erwin; Elisabeth, Pohlmann; Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000256	A1	20030103	WO 2002-EP6237	20020607
WO 2003000256	A9	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10129725	A1	20030102	DE 2001-10129725	20010620
CA 2451258	A1	20030103	CA 2002-2451258	20020607
AU 2003012982	A1	20030108	AU 2002-312982	20020607
EE 200400020	A	20040415	EE 2004-20	20020607
EP 1411932	A1	20040428	EP 2002-738154	20020607
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010941	A	20040608	BR 2002-10941	20020607
CN 1523986	A	20040825	CN 2002-812411	20020607
HU 2004000240	A2	20040830	HU 2004-240	20020607
JP 2004534083	T	20041111	JP 2003-506901	20020607
NZ 530223	A	20050729	NZ 2002-530223	20020607
MX 2003PA11519	A	20041028	MX 2003-PA11519	20031211
BG 108443	A	20050331	BG 2003-108443	20031212
ZA 2003009799	A	20041220	ZA 2003-9799	20031218
NO 2003005743	A	20040217	NO 2003-5743	20031219
US 2004242660	A1	20041202	US 2004-481297	20040628
IN 2004DN04054	A	20070427	IN 2004-DN4054	20041220
PRIORITY APPLN. INFO.:				DE 2001-10129725 A 20010620
				WO 2002-EP6237 W 20020607
				IN 2003-DN2042 A3 20031128

OTHER SOURCE(S): MARPAT 138:89797
GI


L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to combinations of (A) oxazolidinones I [R1 = 5-X-2-thienyl (X = Cl, Br, Me, CF₃); R2 = DA; A = phenylene; D = 5- or 6-membered heterocyclic ring containing S, N or O; R4 = R8 = H], or their pharmaceutically acceptable salts, hydrates, prodrugs or their mixts. and (B) other pharmaceutically active ingredients; to a method for producing said combinations; and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. Thus, the claimed oxazolone II was prepared from epoxide III via epoxide ring opening with aniline derivative IV, cyclization with carbonyldiimidazole, and N-acylation with 5-chlorothiophene-2-sulfonyl chloride. II was tested for antithrombotic activity in the arteriovenous shunt model (Rat) after [ED50 = 3 mg/kg (p.o.); IC50 = 0.7 nM]; II had a synergistic effect when used in combination with clopidogrel.

IT 446292-07-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)

RN 446292-07-5 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:609543 CAPLUS
 DOCUMENT NUMBER: 137:169507

TITLE: Preparation of oxazolidinones and their use as inhibitors of human blood-coagulation factor Xa
 Straub, Alexander; Langst, Thomas; Fehrestorff, Josef; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz
 PATENT ASSIGNER(S): Bayer Ag, Germany
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWXBXB
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10105989	A1	20020814	DE 2001-10105989	20010209
CA 2437587	A1	20020822	CA 2002-2437587	20020128
WO 2002064575	A1	20020822	WO 2002-EP857	20020128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, NE, SN, TD, TG				
AU 2002235875	A1	20020828	AU 2002-235875	20020128
EP 1366029	A1	20031203	EP 2002-702317	20020128
EP 1366029	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004521905	T	20040722	JP 2002-564508	20020128
ES 2250612	T3	20060416	ES 2002-2702317	20020128
US 2005080081	A1	20050414	US 2004-470861	20040409
US 7034017	B2	20060425		
US 2006173047	A1	20060803	US 2006-394543	20060331
PRIORITY APPLN. INFO.:				
DE 2001-10105989 A 20010209				
WO 2002-EP857 W 20020128				
US 2004-470861 A3 20040409				

OTHER SOURCE(S): MARPAT 137:169507
 GI

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. I [R1 = (un)substituted aryl or heteroaryl with 1-2 heteroatoms, e.g. N, O, S; R2 = CONR8R9, NR10COR11, N(O)R12R13; R3-R6 = H, halo, alkyl, etc.; R7 = H, alkyl; R8 = H, (un)substituted alkyl, e.g., halo, amino, OH, etc.; R9-R11 = (un)substituted alkyl, e.g., halo, amino, OH, etc.; R8 and R9 are bond together with N atom to form a heterocyclic ring; R10, R11 with N(CO) form a heterocyclic ring; R12 and R13 are bond together with N atom to form a heterocyclic ring; x = 0, 1] were prepared For example, coupling of II, e.g., prepared from 2-[(2S)-oxiranylmethyl]-1H-isindole-1,3(2H)-dione in 3 steps, and 4-chlorobenzoyl chloride provide claimed oxazolidinone III in 89% yield. Oxazolidinone III inhibited human blood-coagulation factor Xa with an IC50 of 20 nM. Compds. I are useful in the area of blood coagulation.

IT 446292-07-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of oxazolidinones and their use as inhibitors of human blood-coagulation factor Xa)

RN 446292-07-5 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

